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Reply
We appreciate that Dr. Puri and his colleagues have exhibited an
interest in our recent report (1) and have contributed their
comments. Because their comments bring up important points, we
would like to extend the discussion.
First, Puri et al. emphasize the superiority of the volumetric
measurements in intravascular imaging studies, compared with single-
frame analysis. Their assertion seems to be based mainly on a previous
intravascular ultrasound study that investigated the relationship be-
tween the change in plaque volume and cardiovascular risk factors (2).
lthough it may be true that for some studies, volumetric analysis is
arranted, this is not necessarily the case for our study. Before we
ndergo volumetric measurements, we first need to define the correct
easurements to make given the 3-dimensional structure. To choose
orresponding sites for comparison, we carefully coregistered the
ptical coherence tomographic (OCT) images using landmarks and
nalyzed the serial OCT frames. This procedure has been well
stablished in a variety of OCT and intravascular ultrasound studies
3) and therefore should provide valid data and results.
Second, a histology–OCT imaging comparison study by Kume
t al. (4) reported very high accuracy of OCT measurements for
ntimal plus medial area and intimal thickness. Considering that
edial area is calculated by subtracting the intimal area from
ntimal plus medial area, their results support the legitimacy of
edial area assessment by OCT imaging. We agree that medial
rea calculation should be standardized, as Puri et al. suggest.
Finally, regarding “catheter-induced spasm,” many previous spasm
tudies using coronary angiography have already reported luminal
arrowing even when asymptomatic (5). Because racial differences in
he incidence of spasm have been reported (6), we assume that some
octors in Western countries do not have enough clinical experience
ith this disease, which involves pathogenesis of a wide variety of
schemic heart diseases (7). Therefore, we would like to emphasize the
mportance of spasm in which the tunica media may play a key role.
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Antiarrhythmic Drug
Therapy in 2012
Time to Finally Open Our Eyes!
I read with interest the study by Saksena et al. (1) recently
published in the Journal. Analyzing data from the AFFIRM
(Atrial Fibrillation Follow-Up Investigation of Rhythm Manage-
ment) trial, the authors report that atrial fibrillation patients
treated with amiodarone have higher rates of death (noncardio-
vascular, in particular) and of cardiovascular hospitalization. An
adverse effect of amiodarone, especially among patients with heart
failure, had been previously observed in a subgroup analysis of the
SCD-HeFT (Sudden Cardiac Death in Heart Failure) trial (2), as
well as in retrospective analyses of the CIBIS-II (Cardiac Insuffi-
ciency Bisoprolol Study II) (3), COMET (Carvedilol or Meto-
prolol European Trial) (4), and VALIANT (VALsartan In Acute
myocardial iNfarcTion) (5) trials. Several mechanisms may be
invoked to explain these findings: iatrogenic tachy- and bradyar-
rhythmias (6), drug-induced left ventricular dysynchrony (7),
drug-drug interactions (with digoxin, for example), and extracar-
diac toxicity (thyroid, liver, lungs) (6).
A light at the end of the tunnel had been seen by many
cardiologists with the introduction in clinical practice of droneda-
rone, an iodine-free amiodarone derivate. Indeed, the ATHENA
(A Placebo-Controlled, Double-Blind, Parallel Arm Trial to
Assess the Efficacy of Dronedarone 400 mg bid for the Prevention
of Cardiovascular Hospitalization or Death from Any Cause in
Patients With Atrial Fibrillation/Atrial Flutter) trial showed a
reduction in death and hospitalization for cardiovascular causes in
patients with atrial fibrillation (8). In sharp contrast, a worrisome
increase in mortality associated with the use of dronedarone in the
setting of left ventricular systolic dysfunction was observed in the
ANDROMEDA (Antiarrhythmic Trial with Dronedarone in
Moderate to Severe congestive heart failure Evaluating Morbidity
Decrease) trial (9). More recently, the PALLAS (Permanent
Atrial fibriLLAtion outcome Study using Dronedarone on top of
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March 13, 2012:1038–41standard therapy trial was discontinued prematurely due to an
increase in cardiovascular events in patients with permanent atrial
fibrillation (10), thus forcing both American (11) and European
(12) regulatory agencies to issue official warnings for dronedarone.
It should be noted that the principle difference between amioda-
rone and dronedarone is that the latter lacks the iodine moieties
responsible for thyroid toxicity. Considering that thyroid dysfunc-
tion, even if subclinical, leads to increased cardiovascular mortality
(13), one would expect dronedarone to be safer than amiodarone.
Unfortunately, this is not the case!
Therefore, all class III of antiarrhythmic drugs—not only
amiodarone, but also dronedarone, and even sotalol (1,14)—
need to be put under intense scrutiny. Paradoxically, class III
drugs have always been viewed as a “safe” antiarrhythmic
alternative, especially if compared with class I drugs. The sum
of the available evidence from the literature, however, points to
quite a different and harsher reality. For this reason, the time
has come to put class III antiarrhythmic drugs on the shelf in
the hope that a new and equally potent, but safer, class of
antiarrhythmic drugs be developed. This notion is supported by an
abundance of clinical data and has been recently confirmed through
the study by Saksena et al. (1).
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Reply
We would like to thank Dr. Coceani for his interest in our recent
publication (1) and the opportunity to discuss his comments. He
lists a series of reports that implicate worse cardiovascular (CV)
outcomes with specific type 3 agents in particular subsets of
patients with atrial fibrillation (AF). The observations in these
selected reports have to be put in context of a much larger body of
data that suggests that these agents are effective in restoring sinus
rhythm and do not uniformly increase risk (2). Systematic review
of all AF rhythm control therapy trials has also suggested excess
risk with type 1 drugs. Mixed treatment analyses have also
suggested some differences in efficacy and tolerability of type 3
drugs (3). We think it is important to consider the totality of the
evidence and carefully select antiarrhythmic drugs for individual
patients. We believe that our report can shed light on these varying
results as well as define some new goals and influence designs and
outcome measures of future clinical trials.
Our analysis highlights:
1. The choice of initial antiarrhythmic drug is an independent
variable determining CV outcome.
2. The importance of baseline patient status and comorbidities is
evident in our results. For example, coronary disease and a
history of a heart failure event uniformly adversely affected CV
outcome for all antiarrhythmic drugs analyzed. Specific con-
cerns existed with individual drugs such as selection of sotalol as
initial therapy in women or thyroid disease (treated or un-
treated) with amiodarone.
3. Worsening status of specific comorbidities, such as heart failure
and ischemic heart disease, impacted outcomes.
4. Time-dependent analysis noted fewer CV events occurred in
sinus rhythm.
The available clinical trial data and Dr. Coceani’s highlighted
subgroups probably arrived at their outcomes based on the specific
combinations of these variables and the choice and effectiveness of
the individual antiarrhythmic agent.
We believe that the implications of these observations could be:
1. More critical screening of AF patients for baseline clinical
variables to permit more careful selection of an appropriate
initial antiarrhythmic drug
2. Aggressive treatment of comorbidities to prevent disease pro-
gression
3. Quantitative assessment of sinus rhythm maintenance for
effective rhythm control
We would suggest that Dr. Coceani’s suggestion to “shelve type 3
antiarrhythmic drugs in current use” be restated to “carefully select
